Siloam Vision

Siloam Vision, Inc. is an eye care technology company developing imaging hardware and diagnostic software aimed at reducing preventable blindness, beginning with retinopathy of prematurity (ROP), described by the company as the leading cause of childhood blindness. Its product line comprises iTelegen, software for scheduling, managing and reviewing ROP examinations in a collaborative-care workflow; iTelegen+, which adds artificial intelligence support to that workflow; iCam, a patented scanning laser ophthalmoscope (SLO) camera for ultra-wide field retinal imaging across all ages; and iCam-OCT, an optical coherence tomography system for high-resolution cross-sectional retinal imaging of patients from neonates to adults. The company states its products are not FDA-cleared and are intended solely for investigational use.

The company's AI diagnostic system, known as i-ROP DL, pairs a deep-learning algorithm with a cloud-based telemedicine platform and a vision camera to identify severe ROP in digital images captured on commercially available cameras. The algorithm originated in the i-ROP consortium and underwent validation studies in India, Mongolia and Nepal; the system received FDA breakthrough device designation, described in 2023 press coverage as one of few ophthalmic devices to receive that status in nearly a decade. In parallel, Siloam Vision is developing lower-cost, non-mydriatic ultra-wide field imaging (up to 165 degrees) using infrared laser illumination, with the stated aims of optimizing OCT device cost and performance through super-resolution AI techniques such as generative adversarial networks, and producing commercial-ready SLO and OCT systems for regulatory submission. According to its NIH project summary, a prototype ultra-wide field OCT system had been used in more than 2,000 ROP exams but was too expensive as built for commercialization.

Founding story

Siloam Vision was founded by ophthalmologists Dr. J. Peter Campbell and Dr. R.V. Paul Chan, both leaders of the i-ROP consortium, an imaging and informatics research group that has worked on retinopathy of prematurity since 2010. The consortium was originally started in 2011 and led by Dr. Michael F. Chiang, later director of the National Eye Institute, while he was at Oregon Health & Science University; Campbell and Chan subsequently led it. The company's own account of its origins also names Degang Wang, Tony Sun and Karyn Jonas among the founders, and attributes the founding motivation to experiences providing eye care to blind children in developing countries and to the absence of affordable technology to prevent ROP blindness in underserved regions.

Business model

Siloam Vision develops and intends to commercialize diagnostic hardware (SLO and OCT retinal cameras) together with ROP examination management and AI diagnostic software for clinicians and health systems. Development to date has been supported in part by U.S. federal funding, including NIH SBIR-type awards and an SBIR Phase II contract, and distribution reach is being pursued through a partnership with the nonprofit Orbis International.

Traction

A prototype ultra-wide field OCT system has been used in more than 2,000 ROP exams. The i-ROP DL algorithm was validated over a decade of studies in India, Mongolia and Nepal, and the company's AI software for ROP was in clinical trials as of the 2024 NIH project description. The company received a $1.95M NIH award in 2023 and a 2024 NIH grant of $774,486, and HHS records show $2,841,796 in total NIH award actions across two projects. In April 2026 the company announced positive pivotal clinical study results for its iROP-Assist AI platform.

Latest developments

In June 2025 the company announced an SBIR Phase II contract to advance AI-enabled retinal imaging for military readiness, and in May 2025 coverage reported it had earned FDA Breakthrough Device Designation for its OCT technology for preventing infant blindness. In April 2026 it reported positive pivotal clinical study results for the iROP-Assist AI-powered ROP diagnosis platform. NIH award records show continuing actions on both the AI software validation and portable pediatric retinal imaging projects into fiscal 2026.